Early experimental results of colorectal carcinoma chemotherapeutics by liposomal curcuminoids

Curcuminoids had shown anti-proliferation and induce the apoptosis in many cancer cells. It was chosen as the model drug and liposome, a biocompatible and biodegradable carrier was used (liposomal curcuminoids; LPC). The technique was also investigated for the possibility of facilitating the anti-tumor activity of LPC in colorectal cancer (CRC). In-vitro permeation studies in fresh pig colon mucosa; we found that reduced the cumulative amount and flux of LPC. There are 7.8 folds decreasing which compared to the curcuminoids treatment without liposomal encapsulation. Summary the results show that the liposomal encapsulation could enhance and prolong the cytotoxicity of curcuminoids through possibly increase the cellular uptake of curcuminoids in colorectal cancer cell (CRC) lines (CP1 to CP5). Through the use of LPC, the transmucosa drug delivery system (DDS) of liposome encapsulation to the CRC cancer therapy could be made possible.